TRIKAFTA Tablets. FDA Approved

TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) can be ordered by patient or doctor, if the drug has not been approved or is not available in your country. Medvitaz Pharma Solutions can help you from India to get best price/cost of TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) to treat patients with cystic fibrosis (CF).
Category: .

TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets), co-packaged for oral use. Initial U.S. Approval: 2019

TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets) is a prescription medicine for lung disease called cystic fibrosis (CF) in patients.
INDICATIONS AND USAGE
TRIKAFTA is a combination of ivacaftor, a CFTR potentiator, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.
DOSAGE FORMS & STRENGTHS
• Tablets: fixed dose combination containing elexacaftor 100 mg, tezacaftor 50 mg and ivacaftor 75 mg.
Co-packaged with: • Tablets: ivacaftor 150 mg.
Manufactured By: Vertex Pharmaceutical
Prescribing Information URL: Click Here

Access to TRIKAFTA ™ (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets): Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Elexacaftor/tezacaftor/ivacaftor, sold under the brand name Trikafta, is a fixed-dose combination medication used in those that have cystic fibrosis with a f508del mutation. It is made up of a combination of elexacaftor, tezacaftor, and ivacaftor.

It was approved for medical use in the United States in 2019.

In June 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended the approval of elexacaftor/tezacaftor/ivacaftor (Kaftrio) for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.